Shock - Pipeline Review, H1 2012

Description: Shock – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, ‘Shock - Pipeline Review, H1 2012’, provides an overview of the Shock therapeutic pipeline. This report provides information on the therapeutic development for Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shock. ‘Shock - Pipeline Review, H1 2012’ is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Shock.
- A review of the Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Shock pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Shock pipeline depth and focus of Shock therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Shock Therapeutic Products under Development, Key Players in Shock Therapeutics, Shock Pipeline Overview, Shock Pipeline, Shock Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Shock Overview
Therapeutics Development
An Overview of Pipeline Products for Shock
Shock Therapeutics under Development by Companies
Shock Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Shock Therapeutics – Products under Development by Companies
Shock Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Shock Therapeutics Development
Baxter International Inc.
AstraZeneca PLC
Sangart, Inc.
Cytokine PharmaSciences, Inc.
Cardiome Pharma Corp
Green Cross Corporation
MetrioPharm AG
Curacyte AG
Integrated BioTherapeutics, Inc.
Ikaria Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
Shock – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CytoFab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GED-aPC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IK-6003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemoximer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemoximer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IK-6001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylened blue + Nitric Oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP4OX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arginine Vasopressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Activated Protein C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Activated Protein C + Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dopamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glucose-Insulin-Potassium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIF Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetraspan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SEB-HIG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TSS-HIG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SEB-HuMab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-MIF Antibody - Drug Profile
Product Description
Mechanism of Action
R&D Progress
I.V.-Globulin S inj. - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamiasyn - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nalmefene Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Shock Therapeutics – Drug Profile Updates
Shock Therapeutics – Discontinued Products
Shock Therapeutics - Dormant Products
Shock – Product Development Milestones
Featured News & Press Releases
Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables
Number of Products Under Development for Shock, H1 2012
Products under Development for Shock – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Baxter International Inc., H1 2012
AstraZeneca PLC, H1 2012
Sangart, Inc., H1 2012
Cytokine PharmaSciences, Inc., H1 2012
Cardiome Pharma Corp, H1 2012
Green Cross Corporation, H1 2012
MetrioPharm AG, H1 2012
Curacyte AG, H1 2012
Integrated BioTherapeutics, Inc., H1 2012
Ikaria Inc., H1 2012
Sihuan Pharmaceutical Holdings Group Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Shock Therapeutics – Drug Profile Updates

Shock Therapeutics – Discontinued Products

Shock Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Shock, H1 2012
Products under Development for Shock – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2141752/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Shock - Pipeline Review, H1 2012
Web Address: http://www.researchandmarkets.com/reports/2141752/
Office Code: SCD2I35J

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * _______________________
Job Title: ____________________________
Organisation: _________________________
Address: ______________________________
City: _________________________________
Postal / Zip Code: ____________________
Country: ______________________________
Phone Number: ________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  Please transfer funds to:
Account number  833 130 83
Sort code  98-53-30
Swift code  ULSBIE2D
IBAN number  IE78ULSB98533083313083
Bank Address  Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World